Bifidobacterium breve NKU BB 1–13 alleviates age-related cardiac dysfunction by improving colon aging and modulating gut microbiota to influence blood metabolites

Research on aging and age-related diseases holds positive significance for the promotion of healthy aging. This study evaluated the positive effects of Bifidobacterium breve NKU BB 1–13 on D-galactose-induced aged mice and their colon and heart tissues. Bifidobacterium breve NKU BB 1–13 significantly alleviated pathological phenotypes in the hearts and colons of aged mice while improving colonic, cardiac, and serum-related secretory phenotypes. Notably, Bifidobacterium breve inhibits cardiac IGF1R signaling and its associated pathways; enhances intestinal barrier protein expression and activates the colonic Nrf2-Keap1 pathway; and modulates improvements in gut microbiota and blood metabolism. Correlation analysis indicates that Bifidobacterium breve NKU BB 1–13 may alleviate age-related cardiac dysfunction by improving colonic aging and modulating gut microbiota to influence blood metabolites. • Bifidobacterium breve intervention positively impacts aging. • Bifidobacterium breve intervention alleviates colon aging. • Bifidobacterium breve intervention alleviates cardiac dysfunction by inhibiting IGF1R signaling. • Bifidobacterium breve may improve aging by systemic metabolic changes through regulation of gut microbiota.